profit from every $100 of sales.
$0$100
Cytokinetics
$55.14+2.70% today
-8.3% in 1 year
1-year low $53.691-year high $87.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cytokinetics sold, what it kept, and what it did with the cash.
Sales went from $94.6 million in 2022 to $88.0 million in 2025, with -$785 million of profit last year.
SalesProfit
Cytokinetics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cytokinetics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Cytokinetics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 56 | 70 | 95 | 8 | 18 | 88 | |
| – | – | -146 | -323 | -321 | -328 | |
| -94 | -186 | -324 | -496 | -536 | -612 | |
| – | – | -332 | -457 | -493 | -671 | |
| -127 | -215 | -389 | -526 | -590 | -785 | |
| -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 | |
| – | – | -154.6% | -4,284.1% | -1,737.2% | -372.5% | |
| -168.3% | -264.5% | -342.8% | -6,589.7% | -2,902.7% | -695.4% | |
| -228.0% | -305.7% | -411.2% | -6,988.6% | -3,191.1% | -891.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 534 | 841 | 1,015 | 824 | 1,402 | 1,425 |
| Cash | 83 | 113 | 66 | 113 | 95 | 123 |
| Total debt | – | – | 750 | 756 | 789 | 1,284 |
| Total liabilities | 420 | 597 | 1,123 | 1,211 | 1,537 | 2,084 |
| 113 | 244 | -108 | -386 | -135 | -660 | |
| – | – | 90 | 97 | 112 | 120 | |
| – | – | -41.5% | -100.2% | -60.8% | -86.1% | |
| -112.3% | -88.3% | 360.5% | 136.2% | 435.5% | 119.0% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 9 | -143 | -300 | -414 | -396 | -510 | |
| 11 | 49 | 11 | 1 | 4 | 25 | |
| -2 | -191 | -311 | -416 | -400 | -535 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 18 | 27 | 48 | 72 | 98 | 112 |
Valuation
- –
- –
- –
- -11.3×
- 87.2×
- –
- –
- -7.0%
- -10.2%
- 0.0%
Profitability
- -372.5%
- -695.4%
- -891.6%
- -704.6%
- -56.2%
- -92.2%
- 139.7%
- -65.1%
- -59.6%
- 386.4%
Growth
- +9.5%
- –
- −33.8%
- –
- +11.8%
Financial health
- –
- -1.26
- 81.8%
- -5.6×
- 4.21
- 4.21
- 0.08
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 948
Bottom 44%of 868
Bottom 15%of 985
What analysts expect
- Average price target
- $93.67
- Range
- $69.00 – $136.00
- 5 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -1.67 | -1.67 | +0.0% |
| Feb 24, 2026 | -1.50 | -1.48 | −1.4% |
| Nov 5, 2025 | -1.54 | -1.59 | +3.1% |
| Aug 7, 2025 | -1.12 | -1.34 | +16.4% |
| May 6, 2025 | -1.36 | -1.41 | +3.5% |
| Feb 27, 2025 | -1.26 | -1.29 | +2.3% |
| Nov 6, 2024 | -1.36 | -1.27 | −7.1% |
| Aug 8, 2024 | -1.31 | -1.02 | −28.4% |
News
Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCMSeeking Alpha · Aug 28, 2026The newest story we have is from Aug 28, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
14No pass
Benjamin Graham
43No pass
Philip Fisher
22No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
42No pass
Terry Smith
44No pass
Questions about Cytokinetics
Is Cytokinetics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cytokinetics AI analysis
What does Cytokinetics do?
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It is in Biotechnology, based in South San Francisco, CA, United States, with 673 employees.
Does Cytokinetics pay a dividend?
No. Cytokinetics does not pay a dividend at the moment.
Is Cytokinetics stock halal?
Yes. Cytokinetics passes our halal screen: its business is permitted and its debt is 17% of its market value, under the 30% limit. How we check
How has Cytokinetics stock done over the past year?
Down 8.3% over the past twelve months, to $55.14. It traded between $53.69 and $87.26 and is 36.8% below its high.
Who are Cytokinetics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Cytokinetics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.